ARS Pharmaceuticals (SPRY) Change in Receivables (2024 - 2026)

ARS Pharmaceuticals has reported Change in Receivables for 3 years, with the latest figure at $839000.0 in Q1 2026.

• Quarterly Change in Receivables fell 25.62% year-over-year to $839000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.9 million (up 81.83% YoY) and the FY2025 annual result came in at $17.2 million, up 110.46% from the prior year.
• Change in Receivables climbed to $839000.0 in Q1 2026 per SPRY's latest filing, from -$11.2 million in the prior quarter.
• Over five years, Change in Receivables peaked at $14.0 million in Q3 2025 and troughed at -$11.2 million in Q4 2025.
• A 3-year average of $3.7 million and a median of $1.1 million in 2025 frame the typical range for Change in Receivables.
• The widest YoY moves for Change in Receivables: up 1712.03% in 2025, down 251.0% in 2025.
• Over 3 years, Change in Receivables stood at $7.4 million in 2024, then slumped by 251.0% to -$11.2 million in 2025, then surged by 107.51% to $839000.0 in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $839000.0, -$11.2 million, and $14.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.